Canada markets closed

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
6.26-1.04 (-14.25%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 0.57
52-Week Change 3-60.77%
S&P500 52-Week Change 322.38%
52 Week High 322.20
52 Week Low 35.25
50-Day Moving Average 316.67
200-Day Moving Average 315.18

Share Statistics

Avg Vol (3 month) 31.44k
Avg Vol (10 day) 34.36k
Shares Outstanding 512.5M
Implied Shares Outstanding 6N/A
Float 81.14M
% Held by Insiders 10.48%
% Held by Institutions 10.06%
Shares Short (Apr 15, 2024) 456
Short Ratio (Apr 15, 2024) 40.06
Short % of Float (Apr 15, 2024) 40.02%
Short % of Shares Outstanding (Apr 15, 2024) 4N/A
Shares Short (prior month Mar 15, 2024) 456

Dividends & Splits

Forward Annual Dividend Rate 40.6
Forward Annual Dividend Yield 49.58%
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 48.03
Payout Ratio 4N/A
Dividend Date 3Feb 01, 2024
Ex-Dividend Date 4Jan 19, 2024
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-17,290.32%

Management Effectiveness

Return on Assets (ttm)-86.33%
Return on Equity (ttm)-272.63%

Income Statement

Revenue (ttm)420k
Revenue Per Share (ttm)0.49
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -25.42M
Net Income Avi to Common (ttm)-22.76M
Diluted EPS (ttm)-2.05
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)3.38M
Total Cash Per Share (mrq)2.56
Total Debt (mrq)37k
Total Debt/Equity (mrq)6.10%
Current Ratio (mrq)0.91
Book Value Per Share (mrq)0.57

Cash Flow Statement

Operating Cash Flow (ttm)-16.11M
Levered Free Cash Flow (ttm)-11.76M